摘要
目的:探讨噻托溴铵联合布地奈德福莫特罗粉吸入剂(商品名:信必可都保)治疗对慢性阻塞性肺疾病(COPD)患者肺功能、运动耐量及不良反应的影响。方法:遴选118例COPD急性加重期患者进行随机分组(观察组,n=59例;对照组,n=59例),均行常规对症治疗,对照组给予噻托溴铵吸入治疗,观察组基于以上治疗基础给予信必可都保治疗,观察两组治疗前及治疗14d的肺功能指标、运动耐量、动脉气血分析指标和血清生化指标,评估两组药用安全性。结果:治疗14d后,两组患者肺功能指标中平均肺动脉压(MPAP)、肺动脉收缩压(PASP)及肺动脉舒张压(PADP)显著降低(P<0.05),6min步行试验(6MWD)评分有所提高(P<0.05),两组患者动脉气血分析指标中动脉血氧分压(PaO2)显著升高(P<0.05),动脉血二氧化碳分压(PaCO2)显著降低(P<0.05),两组患者血清金属蛋白酶-1组织抑制因子(TIMP-1)、基质金属蛋白酶-9(MMP-9)及晚期糖基化终末产物(AGEs)水平显著降低(P<0.05),可溶性晚期糖基化终末产物受体(sRAGE)水平显著上升(P<0.05),以上指标观察组变化幅度显著大于对照组(P<0.05);观察组和对照组的不良反应总发生率分别为10.17%)和6.78%(P>0.05)。结论:噻托溴铵联合信必可都保治疗COPD急性加重期患者,可明显改善患者肺功能,提高其运动耐量,减轻肺部炎症反应,临床药用安全性良好,适于推广。
Objective:To explore the effects of tiotropium bromide combined with budesonide formoterol powder inhalant(trade name:symbicort turbuhaler)on lung function,exercise tolerance and adverse reactions in patients with chronic obstructive pulmonary disease(COPD).Methods:A total of 118 patients with acute exacerbation of COPD were selected and randomly grouped(observation group,n=59;control group,n=59).All patients were given routine symptomatic treatment,and control group was given tiotropium inhalation treatment,and observation group was given symbicort turbuhaler on the basis of above treatment.The lung function indexes,exercise tolerance,arterial gas blood analysis indexes and serum biochemical indexes were observed in the two groups before treatment and after 14 d of treatment,and the medicinal safety was evaluated in the two groups.Results:After 14 d of treatment,the lung function indexes of mean pulmonary artery pressure(MPAP),pulmonary artery systolic pressure(PASP)and pulmonary artery diastolic pressure(PADP)were significantly decreased in the the two groups(P<0.05),and the 6min walking distance(6MWD)score was improved(P<0.05),and the arterial gas blood analysis index of arterial partial pressure of oxygen(PaO 2)was significantly increased(P<0.05)while the arterial partial pressure of carbon dioxide(PaCO 2)was significantly decreased(P<0.05),and the levels of serum tissue inhibitor of metalloproteinase-1(TIMP-1),matrix metalloproteinase-9(MMP-9)and advanced glycation end products(AGEs)were significantly decreased in the two groups(P<0.05)while the level of soluble receptor for advanced glycation end-product(sRAGE)was significantly increased(P<0.05),and the changes of the above indicators in observation group were significantly greater than those in control group(P<0.05).The total incidence rates of adverse reactions in observation group and control group were 10.17%and 6.78%respectively(P>0.05).Conclusions:Tiotropium bromide combined with symbicort turbuhaler can treat patients with acute exacerbation of COPD,
作者
刘斌
冉献贵
邢青峰
徐琳琳
LIU Bin;RAN Xiangui;XING Qingfeng(Fuyang People's Hospital,Anhui Fuyang 236000,China)
出处
《河北医学》
CAS
2019年第7期1108-1112,共5页
Hebei Medicine
基金
安徽省卫生厅资助基金项目,(编号:20160101765)
关键词
慢性阻塞性肺疾病
噻托溴铵
信必可都保
肺功能
运动耐量
Chronic obstructive pulmonary disease
Tiotropium bromide
Symbicort turbuhaler
Lung function
Exercise tolerance
